Authors

• Ticiana A.B. Leal (ORCID: https://orcid.org/0000-0002-3735-9063)
• Maximilian J. Hochmair (ORCID: https://orcid.org/0000-0002-8673-2450)
• Marcelo Vailati Negrao (ORCID: https://orcid.org/0000-0001-8938-6699)
• Joshua K. Sabari (ORCID: https://orcid.org/0000-0002-1556-1543)
• Timothy F. Burns (ORCID: https://orcid.org/0000-0002-8685-3762)
• Luis Paz-Ares Rodríguez
• Kathryn C. Arbour (ORCID: https://orcid.org/0000-0001-5951-8427)
• William Nassib William
• Nicolas Fasnacht (ORCID: https://orcid.org/0009-0006-7939-7021)
• Bjørn Henning Grønberg (ORCID: https://orcid.org/0000-0001-5744-1534)
• A. Merced
• C. Lindsay
• Martin Reck
• Lu Shun
• Makoto Nishio
• Alexander I. Spira
• Solange Peters
• Frederico Capuzzo
• Nicolas Girard
• Carla Visseren-Grul

Institutions

• Universidad Complutense de Madrid (ES)
• Memorial Sloan Kettering Cancer Center (US)
• The University of Texas MD Anderson Cancer Center (US)
• Emory University (US)
• Eli Lilly (United States) (US)
• Norwegian University of Science and Technology (NO)
• Université Paris-Saclay (FR)
• Cancer Institute (WIA) (IN)
• Centre Hospitalier Universitaire Vaudois (CH)
• Hinge Health (US)
• St Olav's University Hospital (NO)
• Hôpital Orthopédique de la Suisse Romande (CH)
• Virginia Cancer Specialists (US)
• German Center for Lung Research (DE)
• The Christie NHS Foundation Trust (GB)
• National Cancer Institute (MY)
• LungenClinic Grosshansdorf (DE)
• Karl Landsteiner Society (AT)
• Institut für Lungenforschung (DE)
• Japanese Foundation For Cancer Research (JP)
• The Ohio State University (US)
• Institut Curie (FR)
• University of Lausanne (CH)

Publication Details

Journal

Future Oncology

Published

2026-04-06

DOI

https://doi.org/10.1080/14796694.2026.2651961

Primary Topic

Cancer Immunotherapy and Biomarkers

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Eli Lilly and Company
• American Society of Clinical Oncology